Changes are underway…

In December 2024, Rhythm Biosciences (ASX:RHY), a medical technology company transforming cancer diagnostics through innovative diagnostic technologies that predict, detect, characterise, and support early intervention, acquired the Genetype business assets.

Business integration is currently in progress expected to be completed by 1HCY25. 

Investors should visit the Rhythm Biosciences website for more information.